Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to serve as lead plaintiff is June 3, 2025, which requires a motion to the Court [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant settlements, including over $438 million recovered for investors in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders made false and misleading statements related to a secondary stock offering on October 16, 2023 [5]. - The secondary offering was purportedly designed to allow Bain Capital to increase its stake in Cerevel at a discounted price before AbbVie Inc.'s acquisition announcement, which was made just 51 days later at $45 per share, nearly double the offering price [5].

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors may join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move to serve as lead plaintiff by June 3, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders made false and misleading statements related to a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024 [5]. - The secondary stock offering was purportedly designed to allow Bain Capital to increase its stake in Cerevel at a discounted price before AbbVie Inc.'s acquisition announcement [5]. - Following the offering, AbbVie announced its acquisition of Cerevel for $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly in securities class action settlements since 2013 [4].

Core Viewpoint - Cerevel Therapeutics Holdings, Inc. is facing a class action lawsuit from investors who purchased securities during the specified class period, alleging material omissions and misconduct related to a secondary stock offering and misleading statements regarding an acquisition by AbbVie [1][3]. Group 1: Class Action Details - The class action lawsuit represents investors who bought securities between October 11, 2023, and August 1, 2024, with a deadline for filing a lead plaintiff motion set for June 3, 2025 [1]. - The lawsuit claims that Cerevel's secondary stock offering on October 16, 2023, was manipulated by controlling shareholders Bain and Pfizer to allow Bain to increase its stake at a discounted price before AbbVie's acquisition announcement [3]. Group 2: Financial Implications - The complaint alleges that the offering price was significantly lower than the acquisition price of $45 per share announced by AbbVie just 51 days later, resulting in a windfall of over $120 million for Bain [3].

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors may join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by June 3, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been consistently ranked among the top firms in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders made false statements related to a secondary stock offering on October 16, 2023, which allowed Bain Capital to acquire shares at a discounted price before AbbVie Inc.'s acquisition announcement [5]. - Following the acquisition announcement, Cerevel's stock was valued at $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5].

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by June 3, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders, Bain Capital and Pfizer, made false statements related to a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024 [5]. - The secondary stock offering allowed Bain Capital to acquire shares at a discounted price before AbbVie Inc.'s acquisition announcement, which was made just 51 days later at $45 per share, nearly double the offering price [5]. - Bain Capital's discounted purchases from the offering resulted in a windfall of over $120 million when the true details were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in this area [4].

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the “Class Period”); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cer ...

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors may join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by June 3, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders, Bain Capital and Pfizer, made misleading statements related to a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024 [5]. - The secondary stock offering allowed Bain Capital to increase its stake in Cerevel at a discounted price before AbbVie Inc.'s acquisition announcement, which was made 51 days later at $45 per share, nearly double the offering price [5]. - Bain Capital's discounted purchases from the offering resulted in a windfall exceeding $120 million when the acquisition details became public, leading to investor damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, emphasizing their expertise in this area [4].

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for alleged violations of federal securities laws, particularly concerning misleading statements and undisclosed material facts related to Cerevel's stock offerings and acquisition processes [6][4][7]. Group 1: Legal Allegations - The complaint alleges that the defendants made false and/or misleading statements and failed to disclose material facts during Cerevel's secondary stock offering on October 16, 2023, where shares were sold at $22.81 [6]. - Bain Capital is accused of acquiring Cerevel shares while allegedly possessing nonpublic information about AbbVie's interest in acquiring the company, which was later disclosed at a price of $45 per share [6][7]. - The January 18, 2024, Proxy statement regarding the AbbVie acquisition is claimed to have misled investors about the sales process and conflicts of interest, suggesting that Bain and Pfizer orchestrated the process to maximize profits at the expense of public shareholders [6][7]. Group 2: Class Action Details - Investors who sold or disposed of Cerevel stock between October 11, 2023, and August 1, 2024, or held shares as of January 8, 2024, may have been damaged by the defendants' actions and are encouraged to contact the law firm for legal options [1][4]. - The deadline for investors to seek the role of lead plaintiff in the federal securities class action is June 3, 2025 [4]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [8].